Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Japan CRO Fuji Biomedix Applies For Bankruptcy Protection

This article was originally published in PharmAsia News

Executive Summary

Tokyo-based contract research organization Fuji Biomedix applied for bankruptcy protection Oct. 14. The company has a debt of ¥21.8 billion. In 2006, the company entered purchased several companies. However, the rapid expansion also resulted in a ¥15 billion loan from 21 banks. This September, the company found its profit dropping and lacked the ability to get new loans. The biggest shareholder of the company, Toho Yakuhin, has agreed to take over Fuji's pharmacy business Fuji Family Pharmacy and its 81 drug stores. Japanese CRO Association President Katsuo Nakamura commented that the bankruptcy application will not affect the strong growth of CRO business in Japan. (Click here for more - Japanese language

You may also be interested in...

Allogene Takes Step Closer To Off-The-Shelf CAR-Ts

Phase I data presented at ASCO for ALLO-501 offer proof of concept for the CD19 allogeneic CAR-T and a companion drug, ALLO-647, for lymphodepletion. 

Coronavirus Notebook: BARDA Contracting Scrutiny; Part D Cost Sharing

Dispatches from a world turned upside down covering a possible US government investigation into BARDA contracting practices and Medicare Part D plans waiving cost sharing for COVID-19 treatments.

New Testing Prompts New Finding Of NDMA, Cancer Risk In Metformin Products

The US FDA requests several manufacturers recall extended-release metformin based on studies confirming a higher NDMA impurity threshhold; previous testing found no significant risks. 




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts